THE JENNER INSTITUTE
DEVELOPING INNOVATIVE VACCINES

Clinical BioManufacturing Facility

Products Manufactured at the CBF

UNIVERSITY OF OXFORD

2007
- AdCh63 ME-TRAP Batch 1 (malaria)

2008
- AdCh3 NSmut
- Ad6 NSmut
- (hepatitis C)

2009
- AdCh63 MSP1 (malaria)
- VTP1 GMP Starting Material (cancer therapy)

2010
- AdCh63 AMA1 (malaria)
- (malaria) ChAdV63.HIVconsv (HIV)
- AdCh63 ME-TRAP Batch 2 (malaria)

2011
- AdCh63 ME-TRAP Batch 3 (malaria)
- ColoAd1 Master Virus Seed Stock (cancer therapy)

2012
- AdNRGM (prostate cancer)
- ChAd63 CS (malaria)
- ChAdOx1 NP+M1 (influenza)

2013
- ChAd63 PvDBP (vivax malaria)
- ChAdOx1 85A (tuberculosis)
- ChAd63 RH5 GMP Starting Material (malaria)

2014
- ChAdOx1.5T4 (prostate cancer)
- ChAd63 Pfs25-IMX313 (malaria)

2015
- RH5.1 (insect cell derived protein malaria)
- R21c (Pichia derived VLP malaria)

2016
- ChAdOx1 LS2 (malaria)
- ChAdOx2 HAV (Crohn's disease)
- ChAdOx1 MenB.1 (Meningitis B)

2017
- ChAdOx1 Chik (Chikungunya)
- ChAdOx1 MERS (Middle East Respiratory Syndrome Coronavirus)

2018
- ChAdOx1 Zika (Zika)

2019
- ChAdOx2 RabG (Rabies)
- ChAdOx1 Plague (Plague)

2020
- ChAdOx1 nCoV-19 (SARS-CoV-2 virus)
- ChAdOx1 biEBOV (Ebola virus – Sudan and Zaire ebolavirus)